GLP2-TZ (40mg)

GLP2-TZ is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Extensively studied for its potent metabolic effects, GLP2-TZ has demonstrated superior efficacy in glycemic control and weight management across clinical trial programs. It functions by enhancing insulin secretion, improving insulin sensitivity, and significantly reducing appetite through synergistic incretin receptor activation. In late-phase trials, GLP2-TZ achieved mean weight reductions of up to 22% and HbA1c reductions of up to 2.6%, while also showing secondary benefits for obstructive sleep apnea and cardiovascular risk reduction—positioning it as a transformative tool for research into obesity, type 2 diabetes, and metabolic health.